- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00000979
Comparison of ddI Versus Zidovudine in HIV-Infected Patients
Comparison of 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine in Therapy of Patients With HIV Infection
To compare the effectiveness and toxicity of didanosine (ddI) and zidovudine (AZT) in patients with AIDS, advanced AIDS-related complex (ARC), or asymptomatic infection with CD4 counts < 200 cells/mm3.
AZT is effective in reducing mortality in patients with AIDS who receive the drug after the first episode of Pneumocystis carinii pneumonia (PCP) and in patients with advanced ARC. However, AZT therapy has been associated with significant toxicities. In addition, the effectiveness of AZT appears to decrease during the second and third years of therapy. For these reasons, the development of alternative therapy that would be at least as effective but less toxic is of great importance. The drug ddI is an antiviral agent that inhibits replication (reproduction) of HIV with less apparent toxicity than AZT.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
AZT is effective in reducing mortality in patients with AIDS who receive the drug after the first episode of Pneumocystis carinii pneumonia (PCP) and in patients with advanced ARC. However, AZT therapy has been associated with significant toxicities. In addition, the effectiveness of AZT appears to decrease during the second and third years of therapy. For these reasons, the development of alternative therapy that would be at least as effective but less toxic is of great importance. The drug ddI is an antiviral agent that inhibits replication (reproduction) of HIV with less apparent toxicity than AZT.
AMENDED: 9/28/90 Patients are assigned to one of 2 treatments under a double-blind, randomly allocated, experimental design if their duration of prior AZT therapy is 0 to 16 weeks. (Patients who entered with no more than 16 weeks prior AZT and who were randomized to ddI will continue to be dosed at that level, adjusted for weight, and followed as originally planned.) Patients are assigned to one of 3 treatments as explained prior to this amendment if their duration of prior to AZT therapy is greater than 16 weeks. Original design: Patients are assigned to one of three treatments under a double-blind randomly allocated experimental design. ddI will be administered at two dose levels.
It is anticipated that patients will be seen as outpatients every 2 weeks for the first 4 weeks of the study and monthly thereafter. This study continues for at least 18 months after the entry of the first subject.
Studientyp
Einschreibung
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
San Juan, Puerto Rico, 009275800
- San Juan Veterans Administration Med Ctr
-
-
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 900276016
- Children's Hosp of Los Angeles/UCLA Med Ctr
-
Los Angeles, California, Vereinigte Staaten, 90033
- Los Angeles County - USC Med Ctr
-
Palo Alto, California, Vereinigte Staaten, 94304
- Palo Alto Veterans Adm Med Ctr / Stanford Univ
-
San Diego, California, Vereinigte Staaten, 921036325
- Univ of California / San Diego Treatment Ctr
-
Stanford, California, Vereinigte Staaten, 94305
- Stanford Univ School of Medicine
-
Sylmar, California, Vereinigte Staaten, 91342
- Olive View Med Ctr
-
Sylmar, California, Vereinigte Staaten, 91342
- Sepulveda Veterans Adm Med Ctr / Olive View Med Ctr
-
Torrance, California, Vereinigte Staaten, 90502
- Harbor UCLA Med Ctr
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80262
- Univ of Colorado Health Sciences Ctr
-
Denver, Colorado, Vereinigte Staaten, 80262
- Mountain States Regional Hemophilia Ctr / Univ of Colorado
-
-
District of Columbia
-
Washington, District of Columbia, Vereinigte Staaten, 20037
- George Washington Univ Med Ctr
-
Washington, District of Columbia, Vereinigte Staaten, 20009
- Whitman - Walker Clinic
-
-
Florida
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33316
- G E Morey Jr
-
Miami, Florida, Vereinigte Staaten, 331361013
- Univ of Miami School of Medicine
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Northwestern Univ Med School
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rush Presbyterian - Saint Luke's Med Ctr
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Cook County Hosp
-
Hines, Illinois, Vereinigte Staaten, 60141
- Edward Hines Veterans Administration Hosp
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 462025250
- Indiana Univ Hosp
-
-
Kansas
-
Wichita, Kansas, Vereinigte Staaten, 67214
- Univ of Kansas School of Medicine
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Louisiana Comprehensive Hemophilia Care Ctr
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Louisiana State Univ Med Ctr / Tulane Med School
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Tulane Univ School of Medicine
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Charity Hosp / Tulane Univ Med School
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Johns Hopkins Hosp
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Harvard (Massachusetts Gen Hosp)
-
Boston, Massachusetts, Vereinigte Staaten, 02118
- Boston Med Ctr
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Beth Israel Deaconess - West Campus
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Beth Israel Deaconess Med Ctr
-
Springfield, Massachusetts, Vereinigte Staaten, 01199
- Baystate Med Ctr of Springfield
-
Worcester, Massachusetts, Vereinigte Staaten, 01605
- Med Ctr of Central Massachusetts
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- Univ of Massachusetts Med Ctr
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- Univ of Minnesota
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68105
- Nebraska Regional Hemophilia Ctr
-
-
New York
-
Bronx, New York, Vereinigte Staaten, 10461
- Bronx Municipal Hosp Ctr/Jacobi Med Ctr
-
Bronx, New York, Vereinigte Staaten, 10465
- Jack Weiler Hosp / Bronx Municipal Hosp
-
Bronx, New York, Vereinigte Staaten, 10467
- Montefiore Med Ctr / Bronx Municipal Hosp
-
Bronx, New York, Vereinigte Staaten, 10468
- Bronx Veterans Administration / Mount Sinai Hosp
-
Buffalo, New York, Vereinigte Staaten, 14215
- SUNY / Erie County Med Ctr at Buffalo
-
Elmhurst, New York, Vereinigte Staaten, 11373
- City Hosp Ctr at Elmhurst / Mount Sinai Hosp
-
New York, New York, Vereinigte Staaten, 10021
- Cornell Univ Med Ctr
-
New York, New York, Vereinigte Staaten, 10003
- Beth Israel Med Ctr / Peter Krueger Clinic
-
New York, New York, Vereinigte Staaten, 10016
- Bellevue Hosp / New York Univ Med Ctr
-
New York, New York, Vereinigte Staaten, 10021
- Mem Sloan - Kettering Cancer Ctr
-
New York, New York, Vereinigte Staaten, 10025
- Saint Luke's - Roosevelt Hosp Ctr
-
New York, New York, Vereinigte Staaten, 10029
- Mount Sinai Med Ctr
-
Rochester, New York, Vereinigte Staaten, 14642
- Univ of Rochester Medical Center
-
Stony Brook, New York, Vereinigte Staaten, 117948153
- SUNY - Stony Brook
-
Syracuse, New York, Vereinigte Staaten, 13210
- SUNY / State Univ of New York
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 275997215
- Univ of North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke Univ Med Ctr
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27103
- Bowman Gray School of Medicine / Wake Forest Univ
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 452670405
- Holmes Hosp / Univ of Cincinnati Med Ctr
-
Columbus, Ohio, Vereinigte Staaten, 432101228
- Ohio State Univ Hosp Clinic
-
Toledo, Ohio, Vereinigte Staaten, 43699
- Med College of Ohio
-
-
Pennsylvania
-
Hershey, Pennsylvania, Vereinigte Staaten, 170330850
- Milton S Hershey Med Ctr
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Univ of Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15219
- Hemophilia Ctr of Western PA / Univ of Pittsburgh
-
Pittsburgh, Pennsylvania, Vereinigte Staaten
- Univ of Pittsburgh Med School
-
-
South Carolina
-
West Columbia, South Carolina, Vereinigte Staaten, 29169
- Julio Arroyo
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37920
- Univ of Tennessee / E Tennessee Comprehensive Hemophilia Ctr
-
-
Texas
-
Galveston, Texas, Vereinigte Staaten, 77550
- Univ TX Galveston Med Branch
-
Houston, Texas, Vereinigte Staaten, 77030
- Hermann Hosp / Univ Texas Health Science Ctr
-
Houston, Texas, Vereinigte Staaten, 77030
- Texas Children's Hosp / Baylor Univ
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84132
- Univ of Utah School of Medicine
-
-
Virginia
-
Hampton, Virginia, Vereinigte Staaten, 23666
- Dr Stephen L Green
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98105
- Univ of Washington
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53215
- Dr Brian Buggy
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Milwaukee County Med Complex
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53233
- Great Lakes Hemophilia Foundation
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria
Concurrent Medication:
Required:
- Aerosolized pentamidine (300 mg every 4 weeks using a Respirgard II nebulizer). In the event of physiological intolerance, alternative prophylaxis may be: Trimethoprim / sulfamethoxazole 1 DS tab per day or dapsone 50 - 100 mg/day.
Allowed:
Maintenance therapy for active AIDS defining opportunistic infections for patients with 9 to 47 weeks' experience with zidovudine (AZT).
Treatment of opportunistic infections with other than sulfonamide containing drugs:
- Pyrimethamine and sulfadiazine or clindamycin for suppression of toxoplasmosis acquired after study entry; fluconazole or amphotericin B for suppression of cryptococcosis or ketoconazole for candidiasis.
Intravenous acyclovir for up to 10 days. Erythropoietin for patients under the relevant treatment IND. Analgesics, antihistamines, antiemetics, antidiarrheal agents for symptomatic therapy for toxicities.
Isoniazid (INH) if no other acceptable therapy is available.
Metronidazole may be used for single courses of therapy not to exceed 14 days within consecutive 90 day intervals. Note:
- Ketoconazole and dapsone should be taken 2 hours before or 2 hours after taking ddI (amendment 5/20/91).
Concurrent Treatment:
Allowed:
- Blood transfusions for hemoglobin toxicity.
Patients must:
- Have a diagnosis of AIDS or advanced AIDS related complex (ARC), or per 8/09/90 amendment, asymptomatic HIV infection with CD4 count = or < 200 cells/mm3.
- Be either naive to zidovudine (AZT) or have taken AZT for = or < 48 weeks.
- Have ended treatment for acute Pneumocystis carinii pneumonia (PCP) at least 2 weeks before study entry. For patients with 2 months or less experience with AZT, PCP infection will be the single and only AIDS-defining infection and must have been within 120 days of study entry. Per amendment, other AIDS-defining conditions are allowed in the 8 weeks prior to study entry (for patients in the AZT stratum).Only one episode of PCP is permitted unless patient has > 2 months AZT experience in which case > 1 prior episode of PCP infection is allowed.
- Not have experienced a major intolerance to AZT at doses of at least 500 mg if the patient was on AZT therapy for = or < 48 weeks. A major intolerance is defined as recurrent grade 3 or greater toxicity which results in discontinuation of drug.
Allowed:
- Basal cell carcinoma.
- In situ carcinoma of the cervix.
- Occasional premature atrial or ventricular contraction.
- Patients developing new opportunistic infections after study entry will remain on this protocol.
- Patients whose AIDS-defining condition is Kaposi's sarcoma alone must have CD4 cell counts < 300 cells/mm3.
Prior Medication:
Allowed:
- Previous treatment with zidovudine (AZT) up to 48 weeks.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or diseases are excluded:
- Kaposi's sarcoma (KS) with evidence of visceral disease or where KS requires chemotherapy; subjects with localized KS having CD4 counts = or > 200 cells/mm3.
- AIDS-dementia complex = or > stage 2.
- Prior history of acute pancreatitis within past 2 years or chronic pancreatitis.
- Intractable diarrhea.
- History of seizures within past 6 months or currently requiring anticonvulsants for control.
- History of past or current heart disease.
- Presence of a malignancy likely in the investigators opinion to require cytotoxic myelosuppressive chemotherapy during the expected course of this trial.
Concurrent Medication:
Excluded:
- Oral acidifying agents.
- Neurotoxic drugs. NOTE: If patients require therapy for PCP with IV pentamidine, study mediation is stopped.
Patients with the following are excluded:
- Active AIDS defining events. Maintenance therapy for prior AIDS-defining opportunistic infections is permitted.
- Intolerance to AZT at doses of 500 mg because of recurrent grade 3 toxicity or greater which resulted in discontinuation of drug.
- Neoplasms not specifically allowed.
- Previous enrollment in any study of ddI, ddC or d4T.
- > 48 weeks of AZT therapy.
- An opportunistic infection not adequately controlled with suppressive therapies allowed in the protocol.
- Psychological or emotional problems sufficient, in the investigator's opinion, to prevent adequate compliance study therapy.
- Life expectancy = or < 6 months.
Prior Medication:
Excluded:
- Ganciclovir.
- AZT for = or > 48 weeks.
Excluded within 14 days of study entry:
- Erythropoietin (Eprex).
Excluded within 30 days of study entry:
- Anti-HIV therapy other than AZT.
- Biologic response modifiers.
- Other investigational drugs.
- Corticosteroids.
- Neurotoxic drugs.
Excluded within 90 days of study entry:
- Ribavirin.
Prior Treatment:
Excluded within 14 days of study entry:
- Transfusion.
Active alcohol or drug abuse sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Studienstuhl: R Dolin
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Bozzette SA, Hays RD, Berry SH, Kanouse DE. A Perceived Health Index for use in persons with advanced HIV disease: derivation, reliability, and validity. Med Care. 1994 Jul;32(7):716-31. doi: 10.1097/00005650-199407000-00005.
- Fiscus SA, Heggem-Snow A, Troiani L, Wallmark E, Folds JD, Sheff B, van der Horst CM. Transient high titers of HIV-1 in plasma and progression of disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 May 1;9(1):51-7.
- Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med. 1994 Aug 15;121(4):263-8. doi: 10.7326/0003-4819-121-4-199408150-00005.
- Schooley RT. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. AIDS. 1995 Dec;9 Suppl 2:S15-S19.
- Dolin R, Amato DA, Fischl MA, Pettinelli C, Beltangady M, Liou SH, Brown MJ, Cross AP, Hirsch MS, Hardy WD, et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group. Arch Intern Med. 1995 May 8;155(9):961-74. Erratum In: Arch Intern Med 1995 Nov 13;155(20):2255.
- Fichtenbaum CJ, Clifford DB, Powderly WG. Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Oct 1;10(2):169-74. doi: 10.1097/00042560-199510020-00009.
- Spino C, Kahn JO, Dolin R, Phair JP. Predictors of survival in HIV-infected persons with 50 or fewer CD4 cells/mm3. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 15;15(5):346-55. doi: 10.1097/00042560-199708150-00004.
- Richardson D, Liou SH, Kahn JO. Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS Clinical Trials Group protocols 116A and 116B/117. J Acquir Immune Defic Syndr (1988). 1993 Nov;6(11):1212-23.
- Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CS. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. J Infect Dis. 1996 Oct;174(4):696-703. doi: 10.1093/infdis/174.4.696.
- Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CS, Kahn J. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis. 1996 Oct;174(4):704-12. doi: 10.1093/infdis/174.4.704.
- Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, Kagan J. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clin Infect Dis. 2005 Mar 15;40(6):853-8. doi: 10.1086/427877. Epub 2005 Feb 18.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- RNA-Virusinfektionen
- Viruserkrankungen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- Erkrankungen des Immunsystems
- Langsame Viruserkrankungen
- HIV-Infektionen
- Infektionen
- Erworbenes Immunschwächesyndrom
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Reverse-Transkriptase-Inhibitoren
- Inhibitoren der Nukleinsäuresynthese
- Enzym-Inhibitoren
- Anti-HIV-Agenten
- Antiretrovirale Mittel
- Antimetaboliten
- Zidovudin
- Didanosin
Andere Studien-ID-Nummern
- ACTG 116
- 070V1
- ACTG 116-A
- ACTG 116-B/117
- AI454-008
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur HIV-Infektionen
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Niederlande
-
University of MalayaTeleflexRekrutierungCLABSI – Central Line Associated Bloodstream InfectionMalaysia
-
National Taiwan University Hospital Hsin-Chu BranchAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Johns Hopkins UniversityAbgeschlossenCLABSI – Central Line Associated Bloodstream InfectionVereinigte Staaten
-
National Taiwan University HospitalAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
University of ZurichNoch keine RekrutierungCentral Line-associated Bloodstream Infection (CLABSI) | Katheterbedingte Blutstrominfektion
-
Princess Anna Mazowiecka Hospital, Warsaw, PolandNutricia FoundationAktiv, nicht rekrutierendWachstumsfehler | CLABSI – Central Line Associated Bloodstream InfectionPolen
Klinische Studien zur Zidovudin
-
Glaxo WellcomeUnbekanntHIV-InfektionenVereinigte Staaten
-
Glaxo WellcomeAbgeschlossenHIV-InfektionenVereinigte Staaten, Puerto Rico
-
Institut de Recherche pour le DeveloppementEunice Kennedy Shriver National Institute of Child Health and Human Development... und andere MitarbeiterAbgeschlossenHIV-Infektionen | SchwangerschaftThailand
-
Glaxo WellcomeAbgeschlossenHIV-InfektionenVereinigte Staaten
-
Glaxo WellcomeAbgeschlossenHIV-Infektionen | LipodystrophieVereinigte Staaten
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...AbgeschlossenHIV-InfektionenVereinigte Staaten, Puerto Rico
-
ViiV HealthcareAbgeschlossen
-
Universidad Peruana Cayetano HerediaMerck Sharp & Dohme LLCAbgeschlossenHTLV-I-Infektionen | Tropische spastische ParaparesePeru
-
University of Colorado, DenverNational Institute of Allergy and Infectious Diseases (NIAID); University of...Abgeschlossen
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...AbgeschlossenHIV-InfektionenVereinigte Staaten, Puerto Rico